
Paola Rocca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5465457/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genome-wide association study detected novel susceptibility genes for social cognition impairment in people with schizophrenia. World Journal of Biological Psychiatry, 2022, 23, 46-54.	1.3	4
2	Joint structural-functional magnetic resonance imaging features are associated with diagnosis and real-world functioning in patients with schizophrenia. Schizophrenia Research, 2022, 240, 193-203.	1.1	4
3	The Cognitive Assessment Interview (CAI): Association with neuropsychological scores and real-life functioning in a large sample of Italian subjects with schizophrenia. Schizophrenia Research, 2022, 241, 161-170.	1.1	5
4	The Impact of SARS-CoV-2 Infection on Youth Mental Health: A Narrative Review. Biomedicines, 2022, 10, 772.	1.4	19
5	The relative contributions of insight and neurocognition to intrinsic motivation in schizophrenia. NPJ Schizophrenia, 2022, 8, 18.	2.0	0
6	Which factors delay treatment in bipolar disorder? A nationwide study focussed on duration of untreated illness. Microbial Biotechnology, 2021, 15, 1136-1145.	0.9	23
7	Efficacy of Polyunsaturated Fatty Acids (PUFAs) on Impulsive Behaviours and Aggressiveness in Psychiatric Disorders. International Journal of Molecular Sciences, 2021, 22, 620.	1.8	5
8	Accuracy of self-assessment of real-life functioning in schizophrenia. NPJ Schizophrenia, 2021, 7, 11.	2.0	18
9	Updating and characterizing neuroanatomical markers in high-risk subjects, recently diagnosed and chronic patients with schizophrenia: A revised coordinate-based meta-analysis. Neuroscience and Biobehavioral Reviews, 2021, 123, 83-103.	2.9	40
10	Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses. JAMA Psychiatry, 2021, 78, 550.	6.0	89
11	The Management of Prodromal Symptoms of Bipolar Disorder: Available Options and Future Perspectives. Medicina (Lithuania), 2021, 57, 545.	0.8	0
12	Mental Health in Childhood and Adolescence: The Role of Polyunsaturated Fatty Acids. Biomedicines, 2021, 9, 850.	1.4	11
13	Effects of Cognitive Remediation on Cognition, Metacognition, and Social Cognition in Patients With Schizophrenia. Frontiers in Psychiatry, 2021, 12, 649737.	1.3	7
14	Pharmacological Treatment for Social Cognition: Current Evidence. International Journal of Molecular Sciences, 2021, 22, 7457.	1.8	3
15	Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "real-life― Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 109, 110250.	2.5	18
16	The Role of Trauma in Early Onset Borderline Personality Disorder: A Biopsychosocial Perspective. Frontiers in Psychiatry, 2021, 12, 721361.	1.3	21
17	Accuracy of self-reported adherence and therapeutic drug monitoring in a psychiatric emergency ward. Psychiatry Research, 2021, 305, 114214.	1.7	1
18	How Interpersonal Psychotherapy Changes the Brain. Journal of Clinical Psychiatry, 2021, 83, .	1.1	5

#	Article	IF	CITATIONS
19	Borderline Personality Disorder: Risk Factors and Early Detection. Diagnostics, 2021, 11, 2142.	1.3	23
20	Primary Psychosis: Risk and Protective Factors and Early Detection of the Onset. Diagnostics, 2021, 11, 2146.	1.3	8
21	Questionnaire on Attitude towards Research and Care (QuARC): a survey of patients with psychosis. Journal of Mental Health, 2020, 29, 590-596.	1.0	0
22	Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough?. Expert Opinion on Pharmacotherapy, 2020, 21, 47-61.	0.9	24
23	The interplay among psychopathology, personal resources, contextâ€related factors and realâ€life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and nonâ€recovered patients. World Psychiatry, 2020, 19, 81-91.	4.8	96
24	Factors associated with 30-days and 180-days psychiatric readmissions: A snapshot of a metropolitan area. Psychiatry Research, 2020, 292, 113309.	1.7	8
25	The association between insight and depressive symptoms in schizophrenia: Undirected and Bayesian network analyses. European Psychiatry, 2020, 63, 1-21.	0.1	30
26	Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR. Clinical Drug Investigation, 2020, 40, 861-871.	1.1	2
27	The influence of autistic symptoms on social and non-social cognition and on real-life functioning in people with schizophrenia: Evidence from the Italian Network for Research on Psychoses multicenter study. European Psychiatry, 2020, 63, e98.	0.1	20
28	Trauma and psychopathology associated with early onset BPD: an empirical contribution. Journal of Psychiatric Research, 2020, 131, 54-59.	1.5	11
29	Effects of Omega 3 Fatty Acids on Main Dimensions of Psychopathology. International Journal of Molecular Sciences, 2020, 21, 6042.	1.8	12
30	Editorial: Psychosis and Personality Disorders: Do We Need Early Diagnosis for Successful Treatment?. Frontiers in Psychiatry, 2020, 11, 584.	1.3	0
31	Models Predicting Psychosis in Patients With High Clinical Risk: A Systematic Review. Frontiers in Psychiatry, 2020, 11, 223.	1.3	15
32	Effectiveness of psychosocial treatments on symptoms and functional domains in schizophrenia spectrum disorders: a prospective study in a real-world setting. Disability and Rehabilitation, 2019, 41, 2799-2806.	0.9	5
33	Polyunsaturated Fatty Acids: What is Their Role in Treatment of Psychiatric Disorders?. International Journal of Molecular Sciences, 2019, 20, 5257.	1.8	33
34	Early Detection and Outcome in Borderline Personality Disorder. Frontiers in Psychiatry, 2019, 10, 710.	1.3	37
35	Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review. Frontiers in Psychiatry, 2019, 10, 67.	1.3	60
36	Autobiographical memories, identity disturbance and brain functioning in patients with borderline personality disorder: An fMRI study. Heliyon, 2019, 5, e01323.	1.4	19

#	Article	IF	CITATIONS
37	I do not know whether you did that: Abnormal implicit attribution of social causality in patients with schizophrenia. Schizophrenia Research, 2019, 210, 291-293.	1.1	3
38	Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial. Clinical Drug Investigation, 2019, 39, 169-178.	1.1	11
39	Network Analysis Reveals the Latent Structure of Negative Symptoms in Schizophrenia. Schizophrenia Bulletin, 2019, 45, 1033-1041.	2.3	88
40	Assessment of de novo copy-number variations in Italian patients with schizophrenia: Detection of putative mutations involving regulatory enhancer elements. World Journal of Biological Psychiatry, 2019, 20, 126-136.	1.3	12
41	Cross-cultural Validation of the 5-Factor Structure of Negative Symptoms in Schizophrenia. Schizophrenia Bulletin, 2019, 45, 305-314.	2.3	99
42	Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia. JAMA Psychiatry, 2018, 75, 396.	6.0	214
43	Combination of Omega-3 Fatty Acids and Valproic Acid in Treatment of Borderline Personality Disorder: A Follow-Up Study. Clinical Drug Investigation, 2018, 38, 367-372.	1.1	18
44	The complex relationship between self-reported †personal recovery' and clinical recovery in schizophrenia. Schizophrenia Research, 2018, 192, 108-112.	1.1	45
45	Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: Randomized controlled trials vs naturalistic studies. Psychiatry Research, 2017, 247, 257-264.	1.7	32
46	Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial. CNS Drugs, 2017, 31, 809-819.	2.7	19
47	Personal resources and depression in schizophrenia: The role of self-esteem, resilience and internalized stigma. Psychiatry Research, 2017, 256, 359-364.	1.7	49
48	The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 285-294.	1.8	33
49	Pharmacotherapy of personality disorders: what we know and what we have to search for. Future Neurology, 2017, 12, 199-222.	0.9	4
50	Abnormal Sense of Agency in Patients with Schizophrenia: Evidence from Bimanual Coupling Paradigm. Frontiers in Behavioral Neuroscience, 2016, 10, 43.	1.0	46
51	Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life. Neuropsychiatric Disease and Treatment, 2016, 12, 917.	1.0	25
52	Coping strategies in schizoaffective disorder and schizophrenia: Differences and similarities. Psychiatry Research, 2016, 244, 317-323.	1.7	5
53	Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. Schizophrenia Research, 2016, 175, 154-160.	1.1	66
54	Gender differences in 353 inpatients with acute psychosis: The experience of one Psychiatric Emergency Service of Turin. Psychiatry Research, 2015, 227, 192-197.	1.7	5

#	Article	IF	CITATIONS
55	Electroencephalographic connectivity analysis in schizophrenia. Neuroscience Letters, 2015, 604, 145-150.	1.0	7
56	Negative symptoms and everyday functioning in schizophrenia: A cross-sectional study in a real world-setting. Psychiatry Research, 2014, 218, 284-289.	1.7	82
57	The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry, 2014, 13, 275-287.	4.8	346
58	The Specific Level of Functioning Scale: Construct validity, internal consistency and factor structure in a large Italian sample of people with schizophrenia living in the community. Schizophrenia Research, 2014, 159, 144-150.	1.1	64
59	Relative contributions of negative symptoms, insight, and coping strategies to quality of life in stable schizophrenia. Psychiatry Research, 2014, 220, 102-111.	1.7	30
60	Quality of life in stable schizophrenia: The relative contributions of disorganization and cognitive dysfunction. Schizophrenia Research, 2014, 153, 196-203.	1.1	23
61	Substance use disorders in hospitalized psychiatric patients: The experience of one psychiatric emergency service in Turin. Comprehensive Psychiatry, 2014, 55, 1234-1243.	1.5	3
62	Cognitive functioning and insight in schizophrenia and in schizoaffective disorder. Rivista Di Psichiatria, 2014, 49, 77-83.	0.6	5
63	Clinical outcome and length of stay in an Italian Psychiatric Emergency Service. Social Psychiatry and Psychiatric Epidemiology, 2013, 48, 1013-1020.	1.6	13
64	Insight in stable schizophrenia: Relations with psychopathology and cognition. Comprehensive Psychiatry, 2013, 54, 484-492.	1.5	26
65	Prosody recognition and audiovisual emotion matching in schizophrenia: The contribution of cognition and psychopathology. Psychiatry Research, 2013, 205, 192-198.	1.7	33
66	Differential diagnosis between schizophrenia and autism in adulthood: A case report. Neurocase, 2013, 19, 604-612.	0.2	8
67	Nonlinear analysis of electroencephalogram at rest and during cognitive tasks in patients with schizophrenia. Journal of Psychiatry and Neuroscience, 2012, 37, 259-266.	1.4	30
68	La psicoeducazione nella schizofrenia: evidenze di efficacia e peculiarità di intervento su pazienti e familiari. Quaderni Italiani Di Psichiatria, 2012, 31, 157-163.	0.1	0
69	Compulsory admissions of emergency psychiatric inpatients in Turin: The role of diagnosis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 288-294.	2.5	12
70	Cognitive function and competitive employment in schizophrenia: relative contribution of insight and psychopathology. Social Psychiatry and Psychiatric Epidemiology, 2012, 47, 553-561.	1.6	24
71	Predictors of compulsory admission in schizophrenia-spectrum patients: Excitement, insight, emotion perception. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 137-145.	2.5	24
72	Outcome and length of stay in psychiatric hospitalization, the experience of the University Clinic of Turin. Social Psychiatry and Psychiatric Epidemiology, 2010, 45, 603-610.	1.6	28

#	Article	IF	CITATIONS
73	Neuropsychiatric Symptoms Underlying Caregiver Stress and Insight in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2010, 30, 57-63.	0.7	62
74	The Complaint of Oral Malodour: Psychopathological and Personality Profiles. Psychotherapy and Psychosomatics, 2010, 79, 392-394.	4.0	3
75	Relative contributions of psychotic symptoms and insight to quality of life in stable schizophrenia. Psychiatry Research, 2010, 177, 71-76.	1.7	19
76	Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. Trials, 2009, 10, 31.	0.7	21
77	Exploring the role of face processing in facial emotion recognition in schizophrenia. Acta Neuropsychiatrica, 2009, 21, 292-300.	1.0	6
78	Quality of life and psychopathology during the course of schizophrenia. Comprehensive Psychiatry, 2009, 50, 542-548.	1.5	21
79	Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 373-379.	2.5	35
80	Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 405-413.	2.5	49
81	Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia. Comprehensive Psychiatry, 2008, 49, 170-176.	1.5	45
82	Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: Preliminary findings from a naturalistic, retrospective study. Psychiatry and Clinical Neurosciences, 2007, 61, 622-629.	1.0	36
83	Neuropsychological correlates of reality distortion in schizophrenic patients. Psychiatry Research, 2006, 145, 49-60.	1.7	37
84	Managing the aggressive and violent patient in the psychiatric emergency. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 586-598.	2.5	40
85	Depressive and negative symptoms in schizophrenia: different effects on clinical features. Comprehensive Psychiatry, 2005, 46, 304-310.	1.5	65
86	Citalopram Versus Sertraline in Late-Life Nonmajor Clinically Significant Depression. Journal of Clinical Psychiatry, 2005, 66, 360-369.	1.1	45
87	Relationships of Age at Onset With Clinical Features and Cognitive Functions in a Sample of Schizophrenia Patients. Journal of Clinical Psychiatry, 2004, 65, 908-914.	1.1	44
88	Predictors of psychiatric disorders in liver transplantation candidates: Logistic regression models. Liver Transplantation, 2003, 9, 721-726.	1.3	38
89	A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes. Psychiatry Research, 2002, 112, 145-152.	1.7	16
90	Donepezil in the treatment of Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 369-373.	2.5	22

#	Article	IF	CITATIONS
91	Decrease of the D4 dopamine receptor messenger RNA expression in lymphocytes from patients with major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 1155-1160.	2.5	54
92	A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. Journal of Affective Disorders, 2002, 70, 313-317.	2.0	45
93	Treatment of Borderline Personality Disorder With Risperidone. Journal of Clinical Psychiatry, 2002, 63, 241-244.	1.1	91
94	Lymphocyte peripheral benzodiazepine receptor mRNA decreases in obsessive-compulsive disorder. European Neuropsychopharmacology, 2000, 10, 337-340.	0.3	8
95	Peripheral benzodiazepine receptor messenger RNA is decreased in lymphocytes of generalized anxiety disorder patients. Biological Psychiatry, 1998, 43, 767-773.	0.7	54
96	AN ANALYSIS OF LYMPHOCYTE3H-N-METHYL-SCOPOLAMINE BINDING IN NEUROLOGICAL PATIENTS. Brain, 1991, 114, 1759-1770.	3.7	27